AR107974A1 - Análogos de nucleósidos alquinil como inhibidores de rinovirus humanos - Google Patents
Análogos de nucleósidos alquinil como inhibidores de rinovirus humanosInfo
- Publication number
- AR107974A1 AR107974A1 ARP170100737A ARP170100737A AR107974A1 AR 107974 A1 AR107974 A1 AR 107974A1 AR P170100737 A ARP170100737 A AR P170100737A AR P170100737 A ARP170100737 A AR P170100737A AR 107974 A1 AR107974 A1 AR 107974A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- groups selected
- halo
- hydroxy
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Proporciona además composiciones farmacéuticas que comprenden estos compuestos, y composiciones que comprenden estos compuestos con un co-agente terapéutico, y métodos para usar los compuestos y composiciones para el tratamiento de infecciones virales, especialmente HRV. Reivindicación 1: Un compuesto de fórmula (1), donde: R¹ es H, Me, Et, iPr, o ciclopropilo; R² es H, fosfato, difosfato, trifosfato, -P(=X)(OR⁴)₂, -P(=X)(OR⁴)(NR⁵R⁶), o -P(=X)(NR⁵R⁶)₂, y R³ es H o -C(O)R; o R³ y R² tomados juntos forman -P(=X)(OR⁴)- o -P(=X)(NR⁵R⁶)-; X en cada aparición es independientemente O ó S; R⁴ se selecciona de H, fenilo opcionalmente sustituido con uno o dos grupos seleccionados de la lista A, y alquilo C₁₋₄ opcionalmente sustituido con uno o dos grupos seleccionados de halo, -OR, -OC(O)R, -OC(O)-OR, -NR₂, C(O)R, COOR y -C(O)NR₂; cada R⁵ es independientemente H, -C(O)R, COOR, o alquilo C₁₋₄ opcionalmente sustituido con OH, amino, o COOR; cada R⁶ se selecciona independientemente de H, fenilo opcionalmente sustituido con uno o dos grupos seleccionados de la lista A, y alquilo C₁₋₄ opcionalmente sustituido con uno o dos grupos seleccionados de la lista B; cada R es independientemente H o un grupo alquilo C₁₋₄ opcionalmente sustituido con uno a tres grupos seleccionados de halo, hidroxi, CN, amino, alcoxi C₁₋₃, -C(O)R⁷, -OC(O)R⁷, -C(O)-OR⁷, o -OC(O)-OR⁷; R⁷ se selecciona de H, alquilo C₁₋₄ opcionalmente sustituido con uno a tres grupos seleccionados de halo, hidroxi, CN, amino, y alcoxi C₁₋₃, o fenilo opcionalmente sustituido con uno o dos grupos seleccionados de la lista A; la lista A es halo, hidroxi, -NO₂, CN, -OR⁸, -OC(O)R⁸, -OC(O)-OR⁸, -N(R⁸)₂, -C(O)R⁸, COOR⁸, -C(O)N(R⁸)₂, y alquilo C₁₋₃ opcionalmente sustituido con uno a tres grupos seleccionados de halo, hidroxi, CN, amino, y alcoxi C₁₋₃; la lista B es halo, hidroxi, oxo, CN, -OR⁸, -OC(O)R⁸, -OC(O)-OR⁸, -N(R⁸)₂, -C(O)R⁸, COOR⁸ y -C(O)N(R⁸)₂; y R⁸ es independientemente en cada caso seleccionado de H y alquilo C₁₋₄ opcionalmente sustituido con uno a tres grupos seleccionados de halo, hidroxi, CN, amino y alcoxi C₁₋₃, y dos R⁸ unidos al mismo átomo de nitrógeno puede opcionalmente ciclarse para formar un heterociclo de 3 - 7 miembros, que contiene opcionalmente un N, O ó S adicional como miembro del anillo, y puede estar sustituido por uno o dos grupos seleccionados de oxo, halo, -OH, amino, alquilo C₁₋₃, alcoxi C₁₋₃, y haloalquilo C₁₋₃; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201602360R | 2016-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107974A1 true AR107974A1 (es) | 2018-07-04 |
Family
ID=58448587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100737A AR107974A1 (es) | 2016-03-24 | 2017-03-23 | Análogos de nucleósidos alquinil como inhibidores de rinovirus humanos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9988416B2 (es) |
| EP (2) | EP4292658A3 (es) |
| JP (1) | JP7005508B2 (es) |
| CN (1) | CN109311885A (es) |
| AR (1) | AR107974A1 (es) |
| DK (1) | DK3433257T3 (es) |
| ES (1) | ES2962269T3 (es) |
| FI (1) | FI3433257T3 (es) |
| PL (1) | PL3433257T3 (es) |
| PT (1) | PT3433257T (es) |
| TW (1) | TWI746532B (es) |
| UY (1) | UY37166A (es) |
| WO (1) | WO2017163186A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017163186A1 (en) * | 2016-03-24 | 2017-09-28 | Novartis Ag | Alkynyl nucleoside analogs as inhibitors of human rhinovirus |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| DK0920505T3 (da) | 1996-08-16 | 2008-09-08 | Schering Corp | Pattedyrcelleoverfladeantigener og tilhörende reagenser |
| CZ126799A3 (cs) | 1996-10-16 | 1999-07-14 | Icn Pharmaceuticals | Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují |
| AU1102399A (en) | 1997-10-21 | 1999-05-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| ATE376837T1 (de) | 1999-07-12 | 2007-11-15 | Genentech Inc | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| NZ526703A (en) | 2001-01-22 | 2004-12-24 | Merck & Co Inc | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003288675B2 (en) | 2002-12-23 | 2010-07-22 | Medimmune Limited | Antibodies against PD-1 and uses therefor |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| KR20060052681A (ko) | 2003-05-23 | 2006-05-19 | 와이어쓰 | Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도 |
| US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| EP1866339B8 (en) | 2005-03-25 | 2021-12-01 | GITR, Inc. | Gitr binding molecules and uses therefor |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| WO2008156712A1 (en) | 2007-06-18 | 2008-12-24 | N. V. Organon | Antibodies to human programmed death receptor pd-1 |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| AU2009213738B2 (en) | 2008-02-11 | 2015-01-22 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EA201170031A1 (ru) | 2008-07-02 | 2011-08-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | СВЯЗЫВАЮЩИЕ НЕСКОЛЬКО МИШЕНЕЙ БЕЛКИ, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКИМ ДЕЙСТВИЕМ ПО ОТНОШЕНИЮ К TGF-β |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Ｐｄ-１ 길항제 및 그의 사용 방법 |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| JPWO2010030002A1 (ja) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| EP4331604B1 (en) | 2008-12-09 | 2025-03-05 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| TW201031675A (en) * | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| SG174364A1 (en) | 2009-03-20 | 2011-10-28 | Alios Biopharma Inc | Substituted nucleoside and nucleotide analogs |
| RU2646139C1 (ru) | 2009-09-03 | 2018-03-01 | Мерк Шарп И Доум Корп. | Анти-gitr-антитела |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| US9198972B2 (en) | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| CA2804375C (en) | 2010-07-19 | 2018-08-21 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP6284547B2 (ja) | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| TW201542578A (zh) * | 2013-06-26 | 2015-11-16 | Alios Biopharma Inc | 經取代之核苷、核苷酸及其類似物 |
| EA201690526A1 (ru) * | 2013-10-11 | 2017-02-28 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| LT3160476T (lt) * | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
| WO2017163186A1 (en) * | 2016-03-24 | 2017-09-28 | Novartis Ag | Alkynyl nucleoside analogs as inhibitors of human rhinovirus |
-
2017
- 2017-03-21 WO PCT/IB2017/051638 patent/WO2017163186A1/en active Application Filing
- 2017-03-21 ES ES17714300T patent/ES2962269T3/es active Active
- 2017-03-21 FI FIEP17714300.5T patent/FI3433257T3/fi active
- 2017-03-21 PL PL17714300.5T patent/PL3433257T3/pl unknown
- 2017-03-21 DK DK17714300.5T patent/DK3433257T3/da active
- 2017-03-21 PT PT177143005T patent/PT3433257T/pt unknown
- 2017-03-21 EP EP23202131.1A patent/EP4292658A3/en active Pending
- 2017-03-21 EP EP17714300.5A patent/EP3433257B1/en active Active
- 2017-03-21 US US15/465,485 patent/US9988416B2/en active Active
- 2017-03-21 JP JP2018549854A patent/JP7005508B2/ja active Active
- 2017-03-21 CN CN201780031987.5A patent/CN109311885A/zh active Pending
- 2017-03-23 UY UY0001037166A patent/UY37166A/es not_active Application Discontinuation
- 2017-03-23 TW TW106109704A patent/TWI746532B/zh active
- 2017-03-23 AR ARP170100737A patent/AR107974A1/es unknown
-
2018
- 2018-05-08 US US15/974,469 patent/US10428105B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019509316A (ja) | 2019-04-04 |
| TW201736391A (zh) | 2017-10-16 |
| EP4292658A3 (en) | 2024-03-06 |
| PT3433257T (pt) | 2023-11-29 |
| EP3433257B1 (en) | 2023-10-11 |
| US20180258129A1 (en) | 2018-09-13 |
| ES2962269T3 (es) | 2024-03-18 |
| CN109311885A (zh) | 2019-02-05 |
| EP4292658A2 (en) | 2023-12-20 |
| DK3433257T3 (da) | 2024-01-02 |
| WO2017163186A1 (en) | 2017-09-28 |
| UY37166A (es) | 2017-10-31 |
| EP3433257A1 (en) | 2019-01-30 |
| US9988416B2 (en) | 2018-06-05 |
| FI3433257T3 (fi) | 2024-01-08 |
| JP7005508B2 (ja) | 2022-01-21 |
| TWI746532B (zh) | 2021-11-21 |
| PL3433257T3 (pl) | 2024-02-12 |
| US20170275329A1 (en) | 2017-09-28 |
| US10428105B2 (en) | 2019-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR101600A1 (es) | COMPUESTOS DE SPIRO[3H-INDOL-3,2-PIRROLIDIN]-2(1H)-ONA Y DERIVADOS COMO INHIBIDORES DE MDM2-p53 | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR110298A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR106070A1 (es) | Benzamidas sustituidas con isoxazolina como insecticidas | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| JOP20190115B1 (ar) | مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR097948A1 (es) | Inhibidores de la proteasa de cisteína catepsina | |
| AR101638A1 (es) | Combinaciones de inhibidores de la recaptación de serotonina-norepinefrina (irsn) y ligandos del receptores sigma | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR107974A1 (es) | Análogos de nucleósidos alquinil como inhibidores de rinovirus humanos | |
| AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb |